Liminatus Pharma, Inc.
LIMN
$0.14
$0.013.85%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | -- | 499.82% | 1,441.49% | -- | -- |
| Total Receivables | -- | -- | -- | -- | -- |
| Inventory | -- | -- | -- | -- | -- |
| Prepaid Expenses | -- | 4.76% | 378.90% | -- | -- |
| Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
| Other Current Assets | -- | -- | -- | -- | -- |
| Total Current Assets | -- | -90.52% | -72.55% | -- | -- |
|
|
|||||
| Total Current Assets | -- | -90.52% | -72.55% | -- | -- |
| Net Property, Plant & Equipment | -- | 1,255.56% | 1,180.00% | -- | -- |
| Long-term Investments | -- | -- | -- | -- | -- |
| Goodwill | -- | -- | -- | -- | -- |
| Total Other Intangibles | -- | -- | -- | -- | -- |
| Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
| Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
| Total Other Assets | -- | -- | 0.24% | -- | -- |
| Total Assets | -- | -90.52% | -70.24% | -- | -- |
|
|
|||||
| Total Accounts Payable | -- | -60.75% | -52.29% | -- | -- |
| Total Accrued Expenses | 20,136.36% | -93.42% | -93.82% | -- | -99.94% |
| Short-term Debt | -- | -92.78% | -92.52% | -- | -- |
| Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Liabilities | -- | 4,031.90% | 264.57% | -- | -- |
| Total Other Current Liabilities | -- | 4,031.90% | 264.57% | -- | -- |
| Total Current Liabilities | 262,572.73% | -58.39% | -87.87% | -- | -99.99% |
|
|
|||||
| Total Current Liabilities | 262,572.73% | -58.39% | -87.87% | -- | -99.99% |
| Long-Term Debt | -- | -- | -- | -- | -- |
| Short-term Debt | -- | -92.78% | -92.52% | -- | -- |
| Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Non Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
| Total Other Liabilities | -- | -- | -- | -- | -- |
| Total Liabilities | 265,609.09% | -58.27% | -87.35% | -- | -99.99% |
|
|
|||||
| Common Stock & APIC | -- | 211.60% | 211.60% | -- | -100.00% |
| Retained Earnings | -3,635,845.45% | -35.61% | -7.97% | -- | 100.00% |
| Treasury Stock & Other | -- | -- | -- | -- | -- |
| Total Common Equity | -11,954.55% | 49.25% | 91.39% | -- | 99.99% |
|
|
|||||
| Preferred Stock Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Convertible | -- | -- | -- | -- | -- |
| Preferred Stock, Others | -- | -- | -- | -- | -- |
| Total Preferred Equity | -- | -- | -- | -- | -- |
|
|
|||||
| Total Common Equity | -11,954.55% | 49.25% | 91.39% | -- | 99.99% |
| Total Preferred Equity | -- | -- | -- | -- | -- |
| Total Minority Interest | -- | -- | -- | -- | -- |
| Total Equity | -11,954.55% | 49.25% | 91.39% | -- | 99.99% |
|
|
|||||